We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-9.26%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$321M
AUM Growth
-$44.2M
(-12%)
Cap. Flow
+$330K
Cap. Flow
% of AUM
0.1%
Top 10 Holdings %
Top 10 Hldgs %
50.52%
Holding
83
New
10
Increased
22
Reduced
13
Closed
8
Top Buys
| 1 |
TSVT
2seventy bio
TSVT
|
+$6.24M |
| 2 |
Cytokinetics
CYTK
|
+$4.89M |
| 3 |
Axogen
AXGN
|
+$4.18M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$3.04M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$2.59M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$24.1M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
+$8.48M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$5.93M |
| 4 |
LYRA
LYRA THERAPEUTICS INC
LYRA
|
+$1.48M |
| 5 |
Revolution Medicines
RVMD
|
+$1.15M |
Sector Composition
| 1 | Healthcare | 82.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $41.3M | 12.83% |
565,000
| – | – |
|
2
Stereotaxis
STXS
$160M
| $21.6M | 6.72% |
13,680,554
| – | – |
|
|
3
Cytokinetics
CYTK
$11.2B
| $14.1M | 4.39% |
479,538
+146,804
| +44% | +$4.89M |
|
4
IDEAYA Biosciences
IDYA
$3.55B
| $13.5M | 4.19% |
499,820
+20,000
| +4% | +$507K |
|
|
5
Revolution Medicines
RVMD
$39.3B
| $13.1M | 4.08% |
473,394
-38,891
| -8% | -$1.15M |
|
6
Ascendis Pharma A/S
ASND
$17.5B
| $12.8M | 3.97% |
136,212
+1,000
| +0.7% | +$93.6K |
|
7
iShares Biotechnology ETF
IBB
$9.23B
| $12.5M | 3.9% |
102,500
| – | – |
|
|
BPMC
8
DELISTED
Blueprint Medicines
BPMC
| $12.5M | 3.9% |
249,521
-2,000
| -0.8% | -$107K |
|
|
MRUS
9
DELISTED
Merus
MRUS
| $11.4M | 3.56% |
484,870
+100,000
| +26% | +$2.43M |
|
10
Xenon Pharmaceuticals
XENE
$6.55B
| $9.58M | 2.98% |
280,538
| – | – |
|
|
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $8.94M | 2.78% |
52,873
+10,700
| +25% | +$2.01M |
|
12
Neurocrine Biosciences
NBIX
$17.2B
| $8.28M | 2.58% |
73,615
-1,000
| -1% | -$105K |
|
|
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
| $7.2M | 2.24% |
586,463
+79,363
| +16% | +$1.04M |
|
14
Syndax Pharmaceuticals
SNDX
$2.08B
| $6.66M | 2.07% |
458,373
+7,500
| +2% | +$142K |
|
15
DexCom
DXCM
$28.4B
| $6.3M | 1.96% |
67,552
| – | – |
|
|
KALV
16
DELISTED
KalVista Pharmaceuticals
KALV
| $5.83M | 1.81% |
605,532
-5,500
| -0.9% | -$56.2K |
|
|
TSVT
17
DELISTED
2seventy bio
TSVT
| $5.67M | 1.76% |
1,447,465
+951,049
| +192% | +$6.24M |
|
18
AtriCure
ATRC
$1.75B
| $5.5M | 1.71% |
125,529
| – | – |
|
|
MORF
19
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $5.31M | 1.65% |
231,748
+25,000
| +12% | +$1.31M |
|
20
Kura Oncology
KURA
$1B
| $5.02M | 1.56% |
550,784
+193,000
| +54% | +$1.96M |
|
|
21
Axogen
AXGN
$2.05B
| $4.68M | 1.46% |
935,894
+603,791
| +182% | +$4.18M |
|
22
BioCryst Pharmaceuticals
BCRX
$2.41B
| $4.62M | 1.44% |
652,000
+83,000
| +15% | +$596K |
|
|
23
Tandem Diabetes Care
TNDM
$1.06B
| $4.58M | 1.43% |
220,708
+110,708
| +101% | +$3.04M |
|
24
Nurix Therapeutics
NRIX
$2.46B
| $4.38M | 1.36% |
556,695
| – | – |
|
25
Alector
ALEC
$167M
| $4.08M | 1.27% |
628,938
-10,000
| -2% | -$64.7K |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML